TNFSF4 and neoplasm: At present a Phase I clinical trial (NCT03894618) of SL-279252 (PD1-Fc-OX40L) is assessing the safety, tolerability, pharmacokinetics, anti-tumor activity and pharmacodynamic effects of this bi-functional fusion protein [108] in patients with advanced solid tumors or lymphomas.